University of Southern California

California Institute of Technology

Sloan-Kettering Institute for Cancer Research

Washington University

Richard J Cote

Lloyd J Old

Yu-Chong Tai

Siyang Zheng

Henry K Lin

Alan N Houghton

Herbert F Oettgen

Ram Datar

Bo Lu

Timothy M Thomson

Michel Bazinet

Mark Edward Thompson

Changhuei Yang

Chongwu Zhou

Allen S Yang

Donna M Morrissey

Cheng Shen

Anirban P Mitra

Edward J Beattie, Jr

Carlos C Cardo

Hannah Brooks

Siddarth Rawal

Computational refocusing-assisted deep learning methods, apparatus, and systems are described. In certain pathology examples, a representative image is generated using a machine learning model trained with uniformly focused training images generated by a Fourier ptychographic digital refocusing procedure and abnormalities are automatedly identified and/or enumerated based on the representative image.

Computational refocusing-assisted deep learning

A microfiltration apparatus and method for separating cells, such as circulating tumor cells, from a sample using a microfiltration device having a top porous membrane and a bottom porous membrane. The porous membranes are formed from parylene and assembled using microfabrication techniques. The porous membranes are arranged so that the pores in the top membrane are offset from the pores in the bottom membrane.

Method and apparatus for microfiltration to perform cell separation

The present invention relates to various methods of detecting DNA methylation and defected DNA. In one embodiment, the invention provides a nanosensor bound to a probe that is complementary to a DNA methylation sequence.

Detection of methylated DNA and DNA mutations

The present invention relates to methods of prognosing urothelial carcinoma. In one embodiment, the present invention provides a method of prognosing urothelial carcinoma by determining expression levels of JUN, MAP2K6, STAT3 and/or ICAM1. In another embodiment, the present invention provides an single prognostic panel made up of eight gene markers. In another embodiment, the present invention provides a single prognostic panel made up of eleven gene markers.

Prognostic panel for urinary bladder cancer

The invention provides parylene membrane filters, filter devices and methods of making them and using them in the mechanical separation of cells and particles by size. The provision of parylene membrane filters with high figures of merit and finely controlled hole sizes allows the separation of cells and particles in a variety of biological and other fluids according to sizes.

Uses of parylene membrane filters

The present invention provides a parylene-based membrane filter device for capturing of circulating tumor cells (CTC). The membrane filter has an array of holes having a predetermined geometric design with precisely controlled size, shape and density. In one aspect, the device has a stack of substantially parallel membrane filters with uniformly-spaced and/or monodispersed holes.

Membrane filter for capturing circulating tumor cells

Four monoclonal antibodies are found which selectively identify prostate cancer. These monoclonals are therefore useful in diagnosis and differential diagnosis of prostate cancer.

Monoclonal antibodies selective for prostate cancer and diagnostic

Four monoclonal antibodies are found which selectively identify prostate cancer. These monoclonals are therefore useful in diagnosis, differential diagnosis and treatment of prostate cancer.

Monoclonal antibodies selective for prostate cancer

Human monoclonal antibodies (HmAbs) capable of reacting with cytokeratin are disclosed. It has been found that HmAbs De8, M54, M307, Hull, C29, Hu22 and Pa24 may be used to detect these cytoskeletal proteins in various cells. By means of these HmAbs the embryological origin of cells may be determined. This information may be used to determine the possible tissue source of metastasized tumors and greatly affects the management of these cancers.

Human monoclonal antibodies to cytokeratin

Human monoclonal antibodies (HmAbs) capable of reacting with cell surface antigens and intracellular components are disclosed. It has been found that HmAbs Ev248, Ch-5, Ch-13, Te-39, Hu44, Ge-1, Gr-431, Gr169 and Sp909 may be used to detect these antigens in various cells. By means of these HmAbs malignant cells may be determined. This information may be used to screen metastasized tumors and primary tumors for tissue source and greatly affects the management of these cancers.

Human monoclonal antibodies to cell surface antigens

Human monoclonal antibodies which specifically bind to antigens found on cell surfaces of renal, lung, and breast cancer cells, intracellular cytoskeletal antigens, nuclear antigens, and cytoplasmic reticular antigens are disclosed. The antibodies are the product of hybridoma cell lines, where the immortal cell line may be, e.g., a human cell line, or a murine cell line.

Human monoclonal antibodies from lymphocytes of patients with malignant

Hybridomas which produce human monoclonal antibodies are disclosed. The hybridomas are formed by fusing lymphocytes from individuals with various cancers to an immortal cell line, such as a myeloma, from, e.g., a human cell line, or a mouse cell line.

Growing community of inventors

St. Louis, MO, United States of America

Richard J Cote